Demographic data of NDMM patients
| . | Non-t(4;14) . | t(4;14) . | |||
|---|---|---|---|---|---|
| Discovery . | Replication . | ||||
| IFM2009 . | IFM2009 . | Toulouse . | MMRF . | T/D . | |
| N | 183 | 24 | 129 | 34 | 71 |
| Median age, y (range) | 60 (35-65) | 56 (41-65) | 63 (43-85) | 58 (36-83) | 59 (39-71) |
| Male, % (no.) | 60.58 (83/137) | 75 (12/16) | 56.59 (73/129) | 67.65 (23/34) | 67.6 (48/71) |
| Female, % (no.) | 39.42 (54/137) | 25 (4/16) | 43.41 (56/129) | 32.35 (11/34) | 32.4 (23/71) |
| ISS1, % (no.) | 35.62 (52/146) | 27.78 (5/18) | 19.23 (20/104) | 23.53 (8/34) | 21.1 (15/71) |
| ISS2, % (no.) | 45.89 (67/146) | 22.22 (4/18) | 46.15 (48/104) | 55.88 (19/34) | 46.5 (33/71) |
| ISS3, % (no.) | 18.49 (27/146) | 50 (9/18) | 34.62 (36/104) | 20.59 (7/34) | 32.4 (23/71) |
| Induction | RVd | RVd | Investigator's choice | RVd | Investigator's choice |
| Stem cell transplant, % (no.) | 46.78 (80/171) | 43.48 (10/23) | 62.02 (80/129) | 61.76 (21/34) | 100 (71/71) |
| Maintenance, % (no.) | 100 (183/183) | 100 (24/24) | 79.65 (90/113) | 44.12 (15/34) | NA |
| . | Non-t(4;14) . | t(4;14) . | |||
|---|---|---|---|---|---|
| Discovery . | Replication . | ||||
| IFM2009 . | IFM2009 . | Toulouse . | MMRF . | T/D . | |
| N | 183 | 24 | 129 | 34 | 71 |
| Median age, y (range) | 60 (35-65) | 56 (41-65) | 63 (43-85) | 58 (36-83) | 59 (39-71) |
| Male, % (no.) | 60.58 (83/137) | 75 (12/16) | 56.59 (73/129) | 67.65 (23/34) | 67.6 (48/71) |
| Female, % (no.) | 39.42 (54/137) | 25 (4/16) | 43.41 (56/129) | 32.35 (11/34) | 32.4 (23/71) |
| ISS1, % (no.) | 35.62 (52/146) | 27.78 (5/18) | 19.23 (20/104) | 23.53 (8/34) | 21.1 (15/71) |
| ISS2, % (no.) | 45.89 (67/146) | 22.22 (4/18) | 46.15 (48/104) | 55.88 (19/34) | 46.5 (33/71) |
| ISS3, % (no.) | 18.49 (27/146) | 50 (9/18) | 34.62 (36/104) | 20.59 (7/34) | 32.4 (23/71) |
| Induction | RVd | RVd | Investigator's choice | RVd | Investigator's choice |
| Stem cell transplant, % (no.) | 46.78 (80/171) | 43.48 (10/23) | 62.02 (80/129) | 61.76 (21/34) | 100 (71/71) |
| Maintenance, % (no.) | 100 (183/183) | 100 (24/24) | 79.65 (90/113) | 44.12 (15/34) | NA |
Cohort demographics for discovery dataset consisting of a t(4;14) specific cohort from TOU, and the t(4;14) subset of IFM2009. The replication cohort was comprised of data from the MMRF CoMMpass trial (IA20) and a Toulouse/Dana-Farber Cancer Institute (T/D) cohort. Patients from the IFM2009 trial without a t(4;14) were used as a comparator set. Per protocol, the induction regimen in IFM2009 was RVd followed by either stem cell transplant or additional cycles of RVd, followed by lenalidomide maintenance. The TOU dataset is composed of t(4;14) patients treated off study in which treatments were by investigator’s choice of standard of care doublet and triplet regimens. Patients in the TOU data set may have received lenalidomide maintenance or continuous therapy at relapse (grouped together in the table). Patients from MMRF included in the replication cohort received RVd, and patients in the T/D dataset received investigator’s choice induction regimens.